| Creator |
|
|---|
| Abstract |
- BACKGROUND: Zebrafish have been used as a vertebrate model to study human cancers such as melanoma,
rhabdomyosarcoma, liver cancer, and leukemia as well as for high-throughput screening of small molecules of
therapeutic value. However, they are just emerging as a model for human brain tumors, which are among the most
devastating and difficult to treat. In this study, we evaluated zebrafish as a brain tumor model by overexpressing a
human version of oncogenic KRAS (KRAS[superscript G12V]).
METHODS: Using zebrafish cytokeratin 5 (krt5) and glial fibrillary acidic protein (gfap) gene promoters, we activated
Ras signaling in the zebrafish central nervous system (CNS) through transient and stable transgenic overexpression.
Immunohistochemical analyses were performed to identify activated pathways in the resulting brain tumors. The
effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated.
RESULTS: We demonstrated that transient transgenic expression of KRAS[superscript G12V] in putative neural stem and/or progenitor cells induced brain tumorigenesis. When expressed under the control of the krt5 gene promoter, KRAS[superscript G12V] induced brain tumors in ventricular zones (VZ) at low frequency. The majority of other tumors were composed mostly of spindle and epithelioid cells, reminiscent of malignant peripheral nerve sheath tumors (MPNSTs). In contrast, when expressed under the control of the gfap gene promoter, KRAS[superscript G12V] induced brain tumors in both VZs and brain parenchyma at higher frequency. Immunohistochemical analyses indicated prominent activation of the canonical RAS-RAF-ERK pathway, variable activation of the mTOR pathway, but no activation of the PI3K-AKT pathway. In a krt5-derived stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor U0126 effectively suppressed this pro-proliferative effects. In a gfap-derived stable and inducible line, expression of oncogenic KRAS led to significantly increased mitotic index in the spinal cord.
CONCLUSIONS: Our studies demonstrate that zebrafish could be explored to study cellular origins and molecular
mechanisms of brain tumorigenesis and could also be used as a platform for studying human oncogene function and
for discovering oncogenic RAS inhibitors.
|
|---|
| Resource Type |
|
|---|
| DOI |
|
|---|
| Date Available |
|
|---|
| Date Issued |
|
|---|
| Citation |
- Ju, B., Chen, W., Orr, B. A., Spitsbergen, J. M., Jia, S., Eden, C. J., ... & Taylor, M. R. (2015). Oncogenic KRAS promotes malignant brain tumors in zebrafish. Molecular Cancer, 14, 18. doi:10.1186/s12943-015-0288-2
|
|---|
| Journal Title |
|
|---|
| Journal Volume |
|
|---|
| Keyword |
|
|---|
| Rights Statement |
|
|---|
| Funding Statement (additional comments about funding) |
- This research was supported by the St. Jude Children’s Research Hospital and ALSAC.
|
|---|
| Publisher |
|
|---|
| Peer Reviewed |
|
|---|
| Language |
|
|---|
| Replaces |
|
|---|
| Additional Information |
- description.provenance : Submitted by Erin Clark (erin.clark@oregonstate.edu) on 2015-03-18T15:30:35Z
No. of bitstreams: 3
license_rdf: 1370 bytes, checksum: cd1af5ab51bcc7a5280cf305303530e9 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes.pdf: 4795453 bytes, checksum: 239b6bf7730cac61063b7216a80db8e0 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes_AdditionalFiles.pdf: 1917513 bytes, checksum: 0c71edff9581f11d556e2a0f5d0d69db (MD5)
- description.provenance : Approved for entry into archive by Erin Clark(erin.clark@oregonstate.edu) on 2015-03-18T15:30:51Z (GMT) No. of bitstreams: 3
license_rdf: 1370 bytes, checksum: cd1af5ab51bcc7a5280cf305303530e9 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes.pdf: 4795453 bytes, checksum: 239b6bf7730cac61063b7216a80db8e0 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes_AdditionalFiles.pdf: 1917513 bytes, checksum: 0c71edff9581f11d556e2a0f5d0d69db (MD5)
- description.provenance : Made available in DSpace on 2015-03-18T15:30:51Z (GMT). No. of bitstreams: 3
license_rdf: 1370 bytes, checksum: cd1af5ab51bcc7a5280cf305303530e9 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes.pdf: 4795453 bytes, checksum: 239b6bf7730cac61063b7216a80db8e0 (MD5)
SpitsbergenJanMicrobiologyOncogenicKRASPromotes_AdditionalFiles.pdf: 1917513 bytes, checksum: 0c71edff9581f11d556e2a0f5d0d69db (MD5)
Previous issue date: 2015-02-03
|
|---|